Main characteristics of allo-SCT patients
| Characteristic . | Whole population (N = 34) . | MAC (n =25) . | RIC (n = 9) . | P* . |
|---|---|---|---|---|
| Age at allo-SCT, y | ||||
| Median | 41 | 36 | 62 | .005 |
| Range | 10-70 | 10-64 | 15-70 | |
| Sex, n (%) | ||||
| Female | 13 (38) | 12 (48) | 1 (11) | .10 |
| Male | 21 (62) | 13 (52) | 8 (89) | |
| Clinical presentation at diagnosis, n (%) | ||||
| Skin involvement | 26 (79) | 21 (84) | 5 (56) | .81 |
| Lymph nodes | 13 (38) | 9 (36) | 4 (44) | |
| Blood involvement | 18 (53) | 15 (60) | 3 (33) | |
| BM infiltration | 29 (85) | 23 (92) | 6 (67) | |
| No. of prior therapies, range | 1-4 | 1-4 | 1-4 | .50 |
| Type of first-line treatment, n (%) | ||||
| AML or ALL-type | 27 (82) | 21 (84) | 6 (67) | .35 |
| NHL-type | 7 (8) | 4 (16) | 3 (33) | |
| Time from diagnosis to allo-SCT, mo | ||||
| Median | 6 | 6 | 8 | .58 |
| Range | 3-63 | 3-63 | 5-16 | |
| Status at allo-SCT, n (%) | ||||
| CR1 | 19 (56) | 15 (60) | 4 (44) | .46 |
| > CR1 or refractory | 15 (44) | 10 (40) | 5 (66) | |
| Donor type, n (%) | ||||
| Related | 11 (32) | 7 (28) | 4 (44) | .43 |
| Unrelated | 23 (68) | 18 (72) | 5 (66) | |
| Stem cell source, n (%) | ||||
| BM | 19 (56) | 16 (64) | 3 (33) | .18 |
| PBSCs | 9 (26) | 6 (24) | 3 (33) | |
| Cord blood | 6 (18) | 3 (12) | 3 (33) | |
| T-cell depletion, n (%) | ||||
| No T-cell depletion | 23 (68) | 19 (76) | 4 (44) | .11 |
| Antithymocyte globulin | 9 (26) | 4 (16) | 5 (66) | |
| Alemtuzumab | 2 (6) | 2 (8) | 0 (0) | |
| Characteristic . | Whole population (N = 34) . | MAC (n =25) . | RIC (n = 9) . | P* . |
|---|---|---|---|---|
| Age at allo-SCT, y | ||||
| Median | 41 | 36 | 62 | .005 |
| Range | 10-70 | 10-64 | 15-70 | |
| Sex, n (%) | ||||
| Female | 13 (38) | 12 (48) | 1 (11) | .10 |
| Male | 21 (62) | 13 (52) | 8 (89) | |
| Clinical presentation at diagnosis, n (%) | ||||
| Skin involvement | 26 (79) | 21 (84) | 5 (56) | .81 |
| Lymph nodes | 13 (38) | 9 (36) | 4 (44) | |
| Blood involvement | 18 (53) | 15 (60) | 3 (33) | |
| BM infiltration | 29 (85) | 23 (92) | 6 (67) | |
| No. of prior therapies, range | 1-4 | 1-4 | 1-4 | .50 |
| Type of first-line treatment, n (%) | ||||
| AML or ALL-type | 27 (82) | 21 (84) | 6 (67) | .35 |
| NHL-type | 7 (8) | 4 (16) | 3 (33) | |
| Time from diagnosis to allo-SCT, mo | ||||
| Median | 6 | 6 | 8 | .58 |
| Range | 3-63 | 3-63 | 5-16 | |
| Status at allo-SCT, n (%) | ||||
| CR1 | 19 (56) | 15 (60) | 4 (44) | .46 |
| > CR1 or refractory | 15 (44) | 10 (40) | 5 (66) | |
| Donor type, n (%) | ||||
| Related | 11 (32) | 7 (28) | 4 (44) | .43 |
| Unrelated | 23 (68) | 18 (72) | 5 (66) | |
| Stem cell source, n (%) | ||||
| BM | 19 (56) | 16 (64) | 3 (33) | .18 |
| PBSCs | 9 (26) | 6 (24) | 3 (33) | |
| Cord blood | 6 (18) | 3 (12) | 3 (33) | |
| T-cell depletion, n (%) | ||||
| No T-cell depletion | 23 (68) | 19 (76) | 4 (44) | .11 |
| Antithymocyte globulin | 9 (26) | 4 (16) | 5 (66) | |
| Alemtuzumab | 2 (6) | 2 (8) | 0 (0) | |
ALL indicates acute lymphoblastic leukemia; AML, acute myeloid leukemia; NHL, non-Hodgkin lymphoma; and PBSCs, peripheral blood stem cells.
The t test was used for continuous variables; the Fisher test for categorical variables.